TY - CHAP M1 - Book, Section TI - Vaccines and Immunoglobulins A1 - Hayney, Mary S. A2 - DiPiro, Joseph T. A2 - Talbert, Robert L. A2 - Yee, Gary C. A2 - Matzke, Gary R. A2 - Wells, Barbara G. A2 - Posey, L. Michael PY - 2017 T2 - Pharmacotherapy: A Pathophysiologic Approach, 10e AB - Content UpdateNovember 20, 2017New Vaccine and Recommendations for Shingles: Shingrix is an inactivated recombinant vaccine licensed in the U.S. in October 2017. The vaccine has at least 90% efficacy in preventing shingles and is highly effective in preventing postherpetic neuralgia. It is recommended for healthy adults ages 50 years and older. Based on high efficacy rates, it is recommended over the previous live-attenuated vaccine Zostavax and is also recommended for adults who previously received Zostavax. Shingrix is given intramuscularly in two doses; the second dose is given 2 to 6 months after the first dose. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1149032076 ER -